Tag: Mikael Dolsten
Pfizer’s danuglipron shows promising results in Phase 2b obesity trial
Pfizer Inc. (NYSE: PFE) has announced encouraging topline data from its Phase 2b clinical trial (NCT04707313) investigating danuglipron, an oral Glucagon-like peptide-1 receptor agonist (GLP-1RA), ... Read More
Roivant Sciences, Pfizer create new business for inflammatory disease drug
Roivant Sciences, a US healthcare company, and Pfizer have established a new Vant to develop and commercialize PF-06480605 (now RVT-3101) for inflammatory and fibrotic bowel ... Read More
Pfizer begins phase 1 study of Covid drug candidate PF-07321332
Pfizer said that it has initiated a phase 1 study in the US for assessing the oral antiviral therapeutic PF-07321332 against SARS-CoV-2, the virus that ... Read More
Pfizer opens $200m biologics clinical manufacturing facility in Andover, MA
US pharma giant Pfizer has opened Andover Clinical Manufacturing Facility (ACMF), a new 175,000sft biologics clinical manufacturing facility built with an investment of over $200 ... Read More